University of Minnesota. Driven to Discover.
Vaccine effectiveness was 44% for the H1N1 strain but essentially zero for H3N2.
Researchers find an increase in vaccine virus shedding and seroconversion.
Researchers used CRISPR to modify cells to overexpress human virus receptors.
The H3N2 recommendation reflects a change from the current Northern Hemisphere vaccine.
The experts plan to announce a decision on the H3N2 strain on Mar 21.
Protection against flu was 47% overall and 46% against the predominant H1N1 strain.
For the flu shot, effectiveness was 67%, and for FluMist it was a not-significant 20%.
A cell-based vaccine protected about 10% better than a standard vaccine but not a high-dose version.
Prior vaccination did not reduce the subsequent season's vaccine effectiveness in children 2 to 17 years old.
Save for the 2009-10 pandemic, the season was the worst in recent years.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.